MicroRNA-181b Serves as a Circulating Biomarker and Regulates Inflammation in Heart Failure

Abstract

Heart failure (HF) is the typical terminal stage of cardiac diseases involving inflammatory states. The function of microRNAs (miRNAs) in the progress of HF remains poorly understood. In this study, real-time PCR results showed a decreased expression of miRNA-181b (miR-181b) in HF patients compared with healthy individuals. Besides, miR-181b expressions were negatively correlated with hypersensitive C-reactive protein (hsCRP) levels in the serum of HF patients. Receiver operator characteristic (ROC) curve analysis showed that miR-181b was a diagnostic predictor of HF, and the area under the curve was 0.970 (DCM-induced HF group) and 0.962 (ICM-induced HF group). Strikingly, in HF rats induced by isoproterenol (ISO), the expression of miR-181b of heart tissue was suppressed before tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) increase, as revealed by western blot and real-time PCR. Besides, the overexpression of miR-181b also decreased the expression of TNF-α, IL-1β, and IL-6 in lipopolysaccharide- (LPS-) induced neonatal cardiomyocytes. In conclusion, our results revealed that miR-181b might be a potential biomarker for HF and provided a novel target for anti-inflammatory therapy.

The Regulation Mechanisms and Clinical Application of MicroRNAs in Myocardial Infarction: A Review of the Recent 5 Years

“…Compared with healthy people, the expression of MiR-181b in heart failure patients decreased, while the expression of hypersensitive C-reactive protein (hsCRP) levels increased. The expression of MiR-181b in heart failure rats was negatively correlated with IL-1, TNF-α, and IL-6 ( 61 ). Wang et al proved up-regulation of miR-335 reduced MI damage in rats by reducing oxidative stress, inflammation, and apoptosis, and MAP3K2 was an essential target for miR-335 to exert cardioprotection ( 62 ).…”

A Systematic Review of miRNA and cfDNA as Potential Biomarkers for Liquid Biopsy in Myocarditis and Inflammatory Dilated Cardiomyopathy

“…Evidence : MiR-155 level was measured in 13 studies [ 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 ]. Its overexpression was found mainly in MCI (5 studies) [ 10 , 13 , 14 , 19 , 21 ] and InfDCM (3 studies) [ 12 , 18 , 20 ].…”

“…Only one study identified increased expression of miR-155 in ischemic cardiomyopathy [ 20 ]. The remaining studies did not detect increased miR-155 expression in other myocardial diseases (non-inflammatory DCM [ 11 , 12 , 17 , 18 , 19 ], rheumatic carditis [ 15 ], or hypertrophic cardiomyopathy [ 20 ]). Two studies performed ROC-AUC analysis, one for distinguishing between MCI and healthy subjects (AUC = 0.901) [ 13 ], and one for InfDCM and healthy subjects (AUC = 0.68) [ 12 ].…”

The Role of MicroRNAs in Dilated Cardiomyopathy: New Insights for an Old Entity

“…Moreover, miR-181b expression was suppressed before increasing TNF-α, IL-1β and IL-6 levels in the heart tissue of a rat model of HF induced by isoproterenol. miR-181b overexpression decreased TNF-α, IL-1β and IL-6 expression in a primary culture of rat neonatal cardiomyocytes [ 32 ].…”